Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
European Radiology|January 21, 2011
Metal artifact reduction by dual energy computed tomography using monoenergetic extrapolationFabian Bamberg, Alexander Dierks, Konstantin Nikolaou, et al.
Clinical Nuclear Medicine|December 30, 2014
Paralytic subileus as an adverse effect of amino acid-based nephroprotection in a patient undergoing peptide receptor radionuclide therapyRudolf A Werner, Joachim Brumberg, Alexander Dierks, et al.
Biomedicines|November 21, 2020
Detection Rate of <sup>68</sup>Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation TherapyJoachim Brumberg, Melanie Beckl, Alexander Dierks, et al.
World Journal of Clinical Pediatrics|February 23, 2017
Off-label-use of sulfur-hexafluoride in voiding urosonography for diagnosis of vesicoureteral reflux in children: A survey on adverse eventsAlexander Sauer, Clemens Wirth, Isabel Platzer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 28, 2023
An Intrapatient Dosimetry Comparison of <sup>177</sup>Lu-rhPSMA-10.1 and <sup>177</sup>Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate CancerAndreas Rinscheid, Alexander Gäble, Georgine Wienand, et al.
Journal of Molecular Endocrinology|July 22, 2010
Identification of adrenal genes regulated in a potassium-dependent mannerAlexander Dierks, Urs D Lichtenauer, Simone Sackmann, et al.
EJNMMI Research|April 26, 2024
Biodistribution and radiation dosimetry of [<sup>99m</sup>Tc]Tc-N4-BTG in patients with biochemical recurrence of prostate cancerAndreas Rinscheid, Alexander Gäble, Georgine Wienand, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 9, 2023
Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [<sup>68</sup>Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid CancerThomas Günther, Nadine Holzleitner, Oliver Viering, et al.
Therapeutic Advances in Medical Oncology|October 3, 2022
A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinomaLouisa Hempel, Constantin Lapa, Alexander Dierks, et al.
Pageof 5